Document:

Exhibit 10.24

 

Letter of Agreement for Proposed Second Amendment to Co-Promotion Agreement

 

August 12, 2014

 

Mr. Andre Turenne

Genzyme Corporation

500 Kendall Street

Cambridge, MA 02142

 

Re:  Proposed Second Amendment of Co-Promotion Agreement between Genzyme and Veracyte

 

Dear Andre:

 

This Letter of Agreement, including Exhibit A, attached hereto and incorporated herein by reference (collectively, this “Letter of Agreement”), confirms recent discussions between Veracyte Inc. (“Veracyte”) and Genzyme Corporation (“Genzyme”) regarding certain proposed amendments to the Co-Promotion Agreement between the parties dated as of January 18, 2012, as amended by that certain Letter of Agreement dated April 9, 2013 (as amended, the “Co-Promotion Agreement”).   Capitalized terms used in this Letter of Agreement that are not defined herein shall have the respective meanings ascribed to them in the Co-Promotion Agreement.

 

1.              Binding Intent.  In exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, including but not limited to, the time and effort that the parties have invested to date to negotiate the terms set forth in Exhibit A, the parties hereby agree to negotiate and (subject to Sections 2 and 3 below) enter into a definitive Second Amendment to the Co-Promotion Agreement (“Second Amendment”) that shall contain substantially the same terms and conditions as those set forth on Exhibit A hereto as well as any other terms and conditions as may be mutually agreed upon by the parties.  For the avoidance of doubt, it is understood and agreed that the terms set forth in Exhibit A shall not take effect until such time as they are included in the definitive Second Amendment and the definitive Second Amendment is executed and delivered by the parties and becomes effective by its terms.

 

2.              Timing.  The parties agree to negotiate the Second Amendment in good faith and to use their respective reasonable efforts to execute and deliver the Second Amendment no later than October 15, 2014 (or such later date as may be mutually agreed by the parties in writing) (the “Negotiation Period”).  The parties agree that during the Negotiation Period, neither party shall deliver notice of termination of the Co-Promotion Agreement. In the event the parties are unable to execute and deliver the Second Amendment by the expiration of the Negotiation Period, the Co-Promotion Agreement shall continue in full force and effect unmodified by this Letter of Agreement.

 

1

 

3.              Preparation of Second Amendment; Requisite Approvals.  Counsel for Genzyme will prepare the initial draft of the Second Amendment.  It is understood and agreed that the definitive Second Amendment is subject to the receipt of all requisite approvals by the senior management and/or boards of directors of Genzyme and Veracyte, as the case may be.

 

4.              Confidentiality.  The existence and the terms of this Letter of Agreement and the transactions contemplated herein shall be covered in all respects by Section 7 of the Co-Promotion Agreement (“Confidentiality”).  Genzyme hereby acknowledges and agrees that Veracyte intends to disclose the terms of this Letter of Agreement in accordance with its obligations under the Federal securities laws and regulations. The parties hereby agree that they shall work together to coordinate their communication of this Letter of Agreement, and that such communications shall be subject to terms and conditions of Section 12.7 of the Co-Promotion Agreement.

 

5.              General.  This Letter of Agreement shall be governed by, construed and enforced in accordance with the laws of the State of New York. This Letter of Agreement constitutes the entire agreement and understanding of the parties regarding the proposed terms of the Second Amendment and supersedes all prior agreements and understandings between the parties with respect thereto.  The headings of this Letter of Agreement are not a part of this Letter of Agreement but are merely guides or labels to assist in locating and reading the several sections hereof.  This Letter of Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Signature pages may be exchanged by facsimile.

 

 

	
 
    	
Very   truly yours,
    
	
 
    	
 
    
	
 
    	
Veracyte, Inc.
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Bonnie H. Anderson
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Bonnie   H. Anderson
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
President &   Chief Executive Officer
    

 

The foregoing is agreed to and accepted by the undersigned as of the date first indicated above:

 

Genzyme Corporation

 

	
By:
    	
/s/   David Meeker
    	
 
    
	
 
    	
 
    	
 
    
	
Name:
    	
David   Meeker
    	
 
    
	
 
    	
 
    	
 
    
	
Title:
    	
President &   Chief Executive Officer
    	
 
    

 

2

 

Proposed Second Amendment to Co-Promotion Agreement Between

Veracyte, Inc. and Genzyme Corporation

 

EXHIBIT A

 

SUMMARY OF KEY TERMS

 

Effective Date:  The Second Amendment shall be effective as of January 1, 2015.

 

Term and Termination:  The provisions in Section 11 of the Co-Promotion Agreement regarding Term and Termination shall not change, with the exception that Section 11.5 of the Co-Promotion Agreement shall be amended to provide that neither party shall have the right to deliver a termination notice thereunder on or prior to January 1, 2016 (hence, the Co-Promotion Agreement cannot be terminated for convenience until after June 30, 2016).

 

Financial Terms:  Section 6.1 of the Co-Promotion Agreement will be revised to provide that the compensation paid by Veracyte to Genzyme as Promotion Fees shall be fifteen percent (15%) of Net Revenues received by Veracyte on the Test in Territory A through the effective date of expiration of the Co-Promotion Agreement.

 

Joint Marketing Activities:  Sections 3 and 4 of the Co-Promotion Agreement and the Annual Commercial Plan shall be amended to provide that the parties shall conduct certain joint marketing activities as set forth below:

 

(1)         The parties agree to jointly maintain a brand presence at industry conferences, trade shows, and scientific meetings with the intent of leveraging the strength and unique aspects of each brand to customers.  Each party shall bear its own costs in connection with the joint marketing activities in this Section (1).  For avoidance of doubt, Veracyte will cover all costs associated with Afirma brand related presence at such industry conferences, trade shows, and scientific meetings.

(2)         Each party shall share sales leads and marketing intelligence with the other.

(3)         Genzyme shall continue to provide, at its sole expense, Afirma medical content educational talks in the field focusing solely on Afirma, with a minimum of the equivalent of one program per Genzyme Clinical Sales Associate per half year (approx. 50 per year).

(4)         Genzyme shall continue to reimburse Veracyte for the expense of reprints and the printing of marketing and sales collateral, all for use by the sales force.  Genzyme will continue to cover the expense of storing printed material in a third party warehouse and distributing such printed materials to the field for use by the sales force as requested.

(5)         Genzyme will continue to pay for the expenses related to the support of Genzyme’s sales force.

 

3

 

Other Marketing Activities:  Sections 3 and 4 of the Co-Promotion Agreement and the Annual Commercial Plan shall be amended to provide that Veracyte shall be responsible for all marketing and medical education activities including all expenses related to advertising and mailings, other than those described above under the heading “Joint Marketing Activities.”

 

Genzyme Sales Efforts:  Sections 3 and 4 of the Co-Promotion Agreement and the Annual Commercial Plan shall be amended to provide that the sales activities of Genzyme shall consist solely of: (1) lead generation, qualification and getting the physician to agree to the benefits of Afirma (“front end”); and (2) account support and maintenance, meaning maintaining conversion (“back end”). The parties shall include provisions in the Second Amendment setting forth reasonable performance metrics related to Genzyme’s sales activities, substantial performance of which shall deemed to be material for purposes of Section 11.2 of the Co-Promotion Agreement.

 

Veracyte Sales Efforts:  Sections 3 and 4 of the Co-Promotion Agreement and the Annual Commercial Plan shall be amended to provide that Veracyte shall be solely responsible for all critical account conversion and set-up, as well as all sales activities other than those specifically outlined above in “Genzyme Sales Efforts.”

 

International Sales and Marketing Activities:  The Second Amendment will also include a restructuring of the Co-Promotion Agreement in Territory B pursuant to which Genzyme may continue its efforts in certain specified countries and Veracyte shall regain exclusive rights to all other Territory B countries.   The Second Amendment will modify, remove or terminate the provisions of the Co-Promotion Agreement that relate to Territory B as appropriate, including without limitation Section 6.5.  To the extent the parties mutually desire an agreement for the Test in any country listed in Territory B, they will negotiate the terms and conditions of such agreement, including without limitation the individual sales, marketing and fee structures for each such country, separately.

 

Clinical Development Funding Commitment.  Section 3.4 of the Co-Promotion Agreement shall be amended to provide that Genzyme shall fund the Dutch study in accordance with the protocol and budget (approximately US$170,000) already agreed upon by the parties, which funding shall constitute satisfaction in full of Genzyme’s obligations in Section 3.4 of the Co-Promotion Agreement, with no payments due or payable to Veracyte under this provision other than the costs of the Dutch study.  For the avoidance of doubt, funding from Genzyme for the Dutch Study will not extend beyond the end of 2015 and will not exceed US$170,000 in total.

 

Management and Governance:  The structure set forth in Section 5 of the Co-Promotion Agreement for managing and governing the activities of the parties shall be revised to the extent necessary to take into account the revised sales and marketing responsibilities set forth in this Exhibit A.

 

Document Amendments:  The Second Amendment may contain such other terms and conditions that the parties mutually agree upon and shall amend the Co-Promotion Agreement to the extent necessary or desirable to eliminate conflicts with the terms set forth in this Letter Agreement.  To the extent conflicts remain, the terms of the Second Amendment shall govern.

 

4Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

EMPLOYMENT
AGREEMENT, dated as of June 3, 2014, by and between Sequential Brands Group, Inc.,
a Delaware corporation (the “Company”), and Gary Klein (the “Executive”).

 

WITNESSETH

 

WHEREAS, the Executive
possesses experience in the apparel industry and brand licensing industry and has knowledge, experience and expertise concerning
the type of business and operations to be conducted by the Company; and

 

WHEREAS, the Company
desires to employ the Executive as the Chief Financial Officer of the Company, and the Executive desires to be so employed by the
Company, in each case, upon the terms and subject to the conditions set forth in this Agreement.

 

NOW, THEREFORE, in consideration of the
mutual covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Company and Executive hereby agree as follows:

 

1. Engagement of Executive; Duties.
During the Term (as hereinafter defined in Section 3 below), the Executive shall have the title of Chief Financial Officer of the
Company reporting to the Company’s Chief Executive Officer. The Executive will have such responsibilities, duties, and authority
customarily associated with the position of Chief Financial Officer. All financial areas of the Company shall report to the Executive.
In connection with his employment by the Company, the Executive shall be based in the greater New York metropolitan area.

 

2. Time. The Executive will devote
substantially all of his working hours to his duties hereunder and towards the overall success of the business of the Company,
including but not limited to, financial reporting and oversight, execution and implementation of financial business plans, developing
and achieving budget targets, managing corporate-level expenses, and overall financial leadership of the Company, provided that
nothing contained herein shall be deemed to restrict the Executive from engaging in charitable, religious, civic or community activities,
or from serving on the boards of directors of non-profit organizations and, with the consent of the Board (such consent not to
be unreasonably withheld, delayed or conditioned), other for-profit companies which do not compete with the Company, provided that
such activities do not materially interfere with Executive’s duties and responsibilities under this Agreement.

 

3. Term. The Executive’s engagement
shall commence on January 1, 2014 (the “Effective Date”) and shall continue for three (3) years from the Effective
Date (the “Term”) unless otherwise terminated as provided herein. In the event that the Executive remains an
employee of the Company following expiration of the Term and this Agreement is not extended, he shall be an employee “at
will” and shall not be (i) at any during or following such “at will” employment, entitled to any of the benefits
under this Agreement, or (ii) at any time following such “at will employment”, subject to any of the restrictions (other
than the undertakings contained in Section 6 and the provisions of Section 10, in each case, which shall survive
any termination or non-renewal of this Agreement), contained in this Agreement (including, but not limited to, the non-solicitation
provisions contained in Section 7).

 

    	1

    	 

    

 

4. Compensation.

 

(a)Base Salary. During the Term,
Executive’s base salary will be at a rate of not less than $250,000 per annum for the 2014 calendar year, $300,000 for the
2015 calendar year and $325,000 for the 2016 calendar year (the “Base Salary”). Such Base Salary shall be paid in accordance
with the Company’s payroll practices and policies then in effect.

 

(b)Bonus. During the Term, the
Executive shall be entitled to receive an annual bonus opportunity for each fiscal year (the “Annual Bonus”)
of up to 60% of Base Salary. The Annual Bonus shall be based upon achievement of performance targets established by the Compensation
Committee of the Board (the “Compensation Committee”) from time to time that will be the same as the performance
targets established for the Company’s Chief Executive Officer.

 

(c)
Restricted Stock. Notwithstanding the provisions of any award agreement with respect to any outstanding restricted stock
award granted under the Company’s 2013 Stock Incentive Compensation Plan or under any other equity compensation plan maintained
by the Company, its predecessors or affiliates (the “Restricted Stock”), upon a “Change in Control,”
all unvested shares of Restricted Stock will immediately vest. For purposes of the Restricted Stock, a Change in Control shall
mean any of the following:

 

(1)Any
individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”)
becomes the beneficial owner (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or more of either (A)
the then-outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”) or (B) the
combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors
(the “Outstanding Company Voting Securities”); provided, however, that, for purposes of this Section
4(c)(1), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by an Excluded Person (as defined
below) (ii) any acquisition directly from the Company, (iii) any acquisition by the Company, (iv) any acquisition by any employee
benefit plan (or related trust) sponsored or maintained by the Company or any affiliate or (v) any acquisition by any corporation
pursuant to a transaction that complies with Sections 4(c)(2)(A) or 4(c)(2)(B) below;

 

(2) Consummation
of (i) a reorganization, merger, statutory share exchange or consolidation or similar transaction involving the Company or any
affiliate, (ii) a sale or other disposition of all or substantially all of the assets of the Company, or (iii) the acquisition
of assets or stock of another entity by the Company or any affiliate (each, a “Business Combination”), in each
case unless, following such Business Combination, (A) all or substantially all of the individuals and entities that were the beneficial
owners of the Outstanding Company Common Stock and the Outstanding Company Voting Securities immediately prior to such Business
Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock (or, for a non-corporate
entity, equivalent securities) and the combined voting power of the then-outstanding voting securities entitled to vote generally
in the election of directors (or, for a non-corporate entity, equivalent governing body), as the case may be, of the entity resulting
from such Business Combination (including, without limitation, an entity that, as a result of such transaction, owns the Company
or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially
the same proportions as their ownership immediately prior to such Business Combination of the Outstanding Company Common Stock
and the Outstanding Company Voting Securities, as the case may be or (B) at least a majority of the members of the board of directors
(or, for a non-corporate entity, equivalent governing body) of the entity resulting from such Business Combination were members
of the incumbent board at the time of the execution of the initial agreement or of the action of the board providing for such Business
Combination; or

 

    	2

    	 

    

 

(3)A
complete liquidation or dissolution of the Company.

 

For purposes hereof, the “Excluded Persons”
shall mean William Sweedler, Tengram Capital Partners Gen2 Fund, L.P. and each of their respective Related Parties. For purposes
of hereof, “Related Party” shall mean with respect to any person or entity, any other person or entity which
(i) directly or indirectly, is controlling, controlled by or under common control with such person or entity, or (ii) directly
or indirectly, is advised, managed, administered by such person or entity or any person or entity described in the immediately
preceding clause (i). For purposes of this definition, “control” of a person or entity (including the terms “controlled
by” and “under common control with”) means the power, directly or indirectly, to direct or cause the direction
of the management or policies of such person or entity, whether through ownership of voting securities, the ability to exercise
voting power, or by contract or otherwise.

 

(d)Benefits. Executive shall
receive the employee and fringe benefits generally made available to other executive officers of the Company from time to time,
including health and dental coverage. Executive shall also be added or continued, as the case may be, as an insured under the Company’s
officers and directors insurance and all other polices which pertain to officers of the Company.

 

(e)Reimbursement of Expenses.
The Company shall pay to Executive the reasonable expenses incurred by him in the performance of his duties hereunder, including,
without limitation, expenses related to cell phones, blackberrys and laptop computers and such other expenses incurred in connection
with business related travel or entertainment in accordance with the Company’s policy, or, if such expenses are paid directly
by the Executive, the Company shall promptly reimburse the Executive for such payments in accordance with the Company’s policy,
provided that the Executive properly accounts for such expenses in accordance with the Company’s policy. In addition, the
Executive shall receive a transportation/travel reimbursement in the amount of $1500.00 per month during the Term.

 

(f)Vacation. Executive shall
be entitled to three weeks of paid vacation per year. The Executive shall use his vacation in the calendar year in which it is
accrued.

 

5.Termination of Employment.

 

(a)General. The Executive’s
employment under this Agreement may be terminated prior to the expiration of the Term without any breach of this Agreement only
on the following circumstances:

 

    	3

    	 

    

 

(b)Death. The Executive’s
employment under this Agreement shall terminate upon his death.

 

(c)Disability. If the Executive
suffers a Disability (as defined below in this sub-section (2)), the Company may terminate the Executive’s employment under
this Agreement upon thirty (30) days prior written notice; provided that the Executive has not returned to full time performance
of his duties during such thirty (30) day period. For purposes hereof, “Disability” shall mean the Executive’s
inability to perform his duties and responsibilities hereunder, with or without reasonable accommodation, due to any physical or
mental illness or incapacity, which condition either (i) has continued for a period of 180 days (including weekends and holidays)
in any consecutive 365-day period, or (ii) is projected by the Board in good faith after consulting with a doctor selected by the
Company and consented to by the Executive (or, in the event of the Executive’s incapacity, his legal representative), such
consent not to be unreasonably withheld, that the condition is likely to continue for a period of at least six (6) consecutive
months from its commencement.

 

(d)Good Reason. The Executive
may terminate his employment under this Agreement for Good Reason after the occurrence of any of the Good Reason events set forth
in the following sentence. For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following
events without the Executive’s prior written consent:

 

(i)the failure by the Company
to timely comply with its material obligations and agreements contained in this Agreement;

 

(ii)a material diminution
of the authorities, duties or responsibilities of the Executive set forth in Section 1 above (other than temporarily while the
Executive is physically or mentally incapacitated and unable to properly perform such duties, as determined by the Board in good
faith) or the assignment to Executive of duties materially inconsistent with his position as Chief Financial Officer;

 

(iii) the loss of the title of
Chief Financial Officer;

 

(iv) the involuntary re-location of the Executive to
an office outside of the New York, New York metropolitan area; or

 

(v) a change in the reporting
structure so that the Executive reports to someone other than the Chief Executive Officer;

 

provided, however, that, within ninety (90) days
of any such events having occurred, the Executive shall have provided the Company with written notice that such events have occurred
and afforded the Company thirty (30) days to cure and if the Company does not cure to Executive’s reasonable satisfaction
then Executive terminates his employment within one hundred twenty (120) days following the expiration of such cure period. For
purposes of this Agreement, upon any reduction or diminution in authorities, duties, responsibilities, etc. the basis for determining
whether such reduction or diminution was material shall be deemed to be the greatest authorities, duties, responsibilities held
by Executive and not the authorities, duties, responsibilities held by Executive immediately prior to the most recent diminution
or reduction (e.g., if the Company were to reduce Executive’s duties and then at a subsequent time were to reduce his duties
further, for purposes of determining whether the second event constitutes a Good Reason event, his duties would be compared to
those he held prior to the initial reduction).

 

    	4

    	 

    

 

(e)Without Good Reason. The Executive
may voluntarily terminate his employment under this Agreement without Good Reason upon written notice by the Executive to the Company
at least thirty (30) days prior to the effective date of such termination (which termination the Company may, in its sole discretion,
make effective earlier than the date set forth in the Notice of Termination (as hereinafter defined in sub-section (h) below)).

 

(f)Cause. The Company may terminate
the Executive’s employment under this Agreement for Cause. Termination for “Cause” shall mean termination of
the Executive’s employment because of the occurrence of any of the following as determined by the Board:

 

(i) any gross negligence or the
willful and continued failure by the Executive to substantially perform his obligations under this Agreement (other than any such
failure resulting from the Executive’s incapacity due to a Disability);

 

(ii) the indictment of the Executive
for, or his conviction of or plea of guilty or nolo contendere to, a felony;

 

(iii)
the Executive’s willfully engaging in misconduct (which shall include theft, fraud, or embezzlement) in the performance
of his duties for the Company or violating any statutory or common law duty of loyalty to the Company;

 

(iv) the Executive’s trading
of securities or willful disclosure of non-public information in each case constituting a violation of insider trading laws which
is injurious to the Company, monetarily or otherwise;

 

(v) any chemical dependence of
the Executive which materially and adversely affects the performance of his duties and responsibilities to the Company or any of
its subsidiaries; provided, however, that the taking of prescribed prescription medication shall not constitute a
chemical dependence of the Executive hereunder; or

 

(vi) a material breach by the
Executive of this Agreement.

 

provided, however, that in each case (other than
(ii), (iii) or (iv)), the Company shall have provided the Executive with written notice within ninety (90) days of the event(s)
alleged to constitute Cause, the Executive has been afforded at least thirty (30) days to cure same and has failed to cure the
event(s) within such 30 day period.

 

(g)Without Cause. The Company
may terminate the Executive’s employment under this Agreement without Cause immediately upon written notice by the Company
to the Executive.

 

(h)Notice of Termination. Any
termination of the Executive’s employment by the Company or by the Executive (other than termination by reason of the Executive’s
death) shall be communicated by written Notice of Termination to the other party of this Agreement. For purposes of this Agreement,
a “Notice of Termination” shall mean a written notice which shall indicate the specific termination provision
in this Agreement relied upon and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for
termination of the Executive’s employment under the provision so indicated.

 

    	5

    	 

    

 

(i)Date of Termination. The “Date
of Termination” shall mean (a) if the Executive’s employment is terminated by his death, the date of his death,
(b) if the Executive’s employment is terminated pursuant to subsection 5(c) above, thirty (30) days after Notice of Termination
is given (provided that the Executive shall not have returned to the performance of his duties on a full-time basis during such
thirty (30) day period), (c) if the Executive’s employment is terminated pursuant to subsections 5(d) or 5(f) above, the
date specified in the Notice of Termination after the expiration of any applicable cure periods, (d) if the Executive’s employment
is terminated pursuant to subsection 5(e) above, the date specified in the Notice of Termination which shall be at least thirty
(30) days after Notice of Termination is given, or such earlier date as the Company shall determine, in its sole discretion, (e)
if the Executive’s employment is terminated pursuant to subsection 5(g), the date on which a Notice of Termination is given
and (f) if Executive is terminated upon expiration of the Term, the date of the expiration of the Term.

 

(j)Compensation Upon Termination.

 

(i)Termination for Cause,
without Good Reason or Expiration of Term. If the Executive’s employment shall be terminated upon the expiration of the
Term, by the Company for Cause or by the Executive without Good Reason, the Executive shall receive from the Company: (1) any earned
but unpaid Base Salary through the Date of Termination, paid in accordance with the Company’s standard payroll practices;
(2) reimbursement for any unreimbursed expenses properly incurred and paid in accordance with Section 4(e) through the Date of
Termination; (3) payment for any accrued but unused vacation time in accordance with Company policy; and (4) such benefits, and
other payments, if any, as to which the Executive (and his eligible dependents) may be entitled under, and in accordance with the
terms and conditions of, the employee benefit arrangements, plans and programs of the Company as of the Date of Termination, other
than any severance pay plan ((1) though (4), (the “Amounts and Benefits”), and the Company shall have no further
obligation with respect to this Agreement other than as provided in Section 8 of this Agreement. In addition, any portion of the
Restricted Stock Award or any other outstanding equity or incentive award that remains unvested on the Date of Termination shall
be forfeited as of the Date of Termination.

 

(ii)Termination without
Cause or for Good Reason. If prior to the expiration of the Term, the Executive resigns from his employment hereunder for Good
Reason or the Company terminates the Executive’s employment hereunder without Cause (other than a termination by reason of
death or Disability), then the Company shall pay or provide the Executive the Amounts and Benefits and the following:

 

(1)an amount equal to the Base
Salary the Executive would have received had he remained employed throughout the remainder of the Term, which shall be payable
in full in a lump sum cash payment to be made to the Executive on the date that is thirty (30) days following the Date of Termination;

 

    	6

    	 

    

 

(2)any Annual Bonus earned but
unpaid for a prior year (the “Prior Year Bonus”), which shall be payable in full in a lump sum cash payment
to be made to the Executive on the date that is thirty (30) days following the Date of Termination or the date such bonus would
be paid if Executive had remained an employee of the Company, if later;

 

(3)in the event such resignation
or termination occurs following the Company’s first fiscal quarter of any year, a pro-rata portion of the Executive’s
Annual Bonus for the fiscal year in which the Executive’s termination occurs based on actual results for such year (determined
by multiplying the amount of such Annual Bonus which would be due for the full fiscal year by a fraction, the numerator of which
is the number of days during the fiscal year of termination that the Executive is employed by the Company and the denominator of
which is 365), paid in accordance with Section 4(b) (“Pro Rata Bonus”). The Pro Rata Bonus shall be payable
at the time the Annual Bonus would have been paid if Executive’s employment had not terminated;

 

(4)subject to the Executive’s
timely election of continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”),
with respect to the Company’s group health insurance plans in which the Executive participated immediately prior to the Date
of Termination (“COBRA Continuation Coverage”), the Company shall pay the cost of COBRA Continuation Coverage for the
Executive and his eligible dependents until the earliest of (a) the Executive or his eligible dependents, as the case may be, ceasing
to be eligible under COBRA (or any COBRA-like benefits provided under applicable state law) and (b) eighteen (18) months following
the Date of Termination, (the benefits provided under this sub-section (4), the “Medical Continuation Benefits”);
and

 

(5)
any unvested portion  of the Restricted Stock shall accelerate and become fully vested on the Date of Termination and the
shares covered by the Restricted Stock Award shall be distributed to the Executive on the date that is thirty (30) days following
the Date of Termination (subject to any securities law restrictions).

 

(iii)Termination
upon Death. In the event of the Executive’s death, the Company shall pay or provide to the Executive’s estate:
(1) continued payment of the Executive’s Base Salary for the remainder of the year in which the termination for reason
of death occurs, (2) the Amounts and Benefits, (3) the Prior Year Bonus,
and (4) the Pro Rata Bonus. In addition, the Restricted Stock Award shall vest with respect to the portion of such award that was
scheduled to vest in the year in which the termination for reason of death occurs and such shares covered by the Restricted Stock
Award shall be distributed to the Executive within thirty (30) days of the Date of Termination (subject to any securities law restrictions).
Any other unvested portion of the Restricted Stock Award will be forfeited on the Date of Termination.

 

(iv)Termination upon Disability.
In the event the Company terminates the Executive’s employment hereunder for reason of Disability, the Company shall pay
or provide to the Executive: (1) the Amounts and Benefits, (2) the Prior Year Bonus, (3) a Pro Rata Bonus and (4) the Medical Continuation
Benefits. In addition, the Restricted Stock Award shall vest with respect to the portion of such award that was scheduled to vest
in the year in which the termination for reason of Disability occurs and such shares covered by the Restricted Stock Award shall
be distributed to the Executive within thirty (30) days of the Date of Termination (subject to any securities law restrictions).
Any other unvested portion of the Restricted Stock Award will be forfeited on the Date of Termination.

 

(v)Payments of Compensation
Upon Termination. For the avoidance of doubt, in the event the Executive shall be entitled to receive payments and benefits
pursuant to any one of sub-sections 5(a), (b), (c) or (d) above, he shall be entitled to no payments or benefits under any other
of such sub-sections.

 

(vi) Release of Claims.
Notwithstanding anything in this Agreement to the contrary, as a condition of receiving any payment or benefits under Section 5(j)(ii)
(other than the Amounts and Benefits), the Executive agrees to execute, deliver and not revoke a general release and covenant not
to sue in favor of the Company and its subsidiaries and their respective affiliates in substantially the form attached here to
as Exhibit B (the “Release”), before the date that is thirty (30) days following the Date of Termination. In
the event the Release is not executed and non-revocable prior to the date that is thirty (30) days following the Date of Termination,
all payments and benefits under Section 5(j)(ii) (other than the Amounts and Benefits) shall be forfeited.

 

    	7

    	 

    

 

(vii)No Duty to Mitigate.
The Executive shall not be required to mitigate the amount of any payment provided for in this Section 5 by seeking other employment
or otherwise, nor shall the amount of any payment provided for in this Section 5 be reduced by any compensation earned by Executive
as the result of Executive’s employment by another employer or business or by profits earned by Executive from any other
source at any time before and after the Executive’s date of termination (other than as provided in Section 5(j)(ii)(4)).

 

6.Confidentiality.

 

(a)The
Executive acknowledges that all customer lists and information, vendor or supplier lists and information, inventions, trade secrets,
software and computer code (whether in object code or source code format), databases, know-how or other non-public, confidential
or proprietary knowledge, information or data with respect to the products, prices, marketing, services, operations, finances,
business or affairs of the Company or its subsidiaries and affiliates or with respect to confidential, proprietary or secret
processes, methods, inventions, services, research, techniques, customers (including, without limitation, the identity of the customers
of the Company or its subsidiaries and affiliates and the specific nature of the services provided by the Company or its subsidiaries
and affiliates), employees (including, without limitation, the matters subject to this Agreement) or plans of or with respect to
the Company or its subsidiaries and affiliates or the terms of this Agreement (all of the foregoing collectively hereinafter referred
to as, “Confidential Information”) are property of the Company or its applicable subsidiaries or affiliates.
The Executive further acknowledges that the Company and its subsidiaries and affiliates intend, and make reasonable good faith
efforts, to protect the Confidential Information from public disclosure. Therefore, the Executive agrees that, except as (a) required
by law or regulation or as legally compelled by court order (provided that in such case, the Executive shall promptly notify
the Company of such order, shall cooperate with the Company in attempting to obtain a protective order or to otherwise restrict
such disclosure, and shall only disclose Confidential Information to the minimum extent necessary to comply with any such law,
regulation or order) or (b) required in order to enforce his rights under this Agreement or any other agreement with the Company
and/or its affiliates, during the Term and at all times thereafter, the Executive shall not, directly or indirectly, divulge, transmit,
publish, copy, distribute, furnish or otherwise disclose or make accessible any Confidential Information, or use any Confidential
Information for the benefit of anyone other than the Company and its subsidiaries and affiliates, unless and to the extent that
the Confidential Information becomes generally known to and available for use by the general public by lawful means and other than
as a result of the Executive’s acts or omissions or such disclosure is necessary in the course of the Executive’s proper
performance of his duties under this Agreement.

 

    	8

    	 

    

 

 

(b)The Company and its subsidiaries and affiliates do
not wish to incorporate any unlicensed or unauthorized material into their products or services. Therefore, the Executive agrees
that he will not disclose to the Company, use in the Company's business, or cause the Company to use, any information or material
which is a trade secret, or confidential or proprietary information, of any third party, including, but not limited to, any former
employer, competitor or client, unless the Company has a right to receive and use such information or material. The Executive will
not incorporate into his work any material or information which is subject to the copyrights of any third party unless the Company
has a written agreement with such third party or otherwise has the right to receive and use such material or information.

 

7.Covenants.

 

(a) Nonsolicitation.

 

(i) Employees. The Executive
shall not, while he is employed by the Company and during the one- year period following his termination of employment for any
reason (the “Restricted Period”), directly or indirectly, (1) employ, cause to be employed or hired, recruit,
solicit for employment or otherwise contract for the services of, any individual who was or is an employee of the Company or any
of its subsidiaries or affiliates; (2) otherwise induce or attempt to induce any employee of the Company or any of its subsidiaries
or affiliates to terminate such individual’s employment with the Company or such subsidiary or affiliate, or in any way interfere
with the relationship between the Company or any such subsidiary or affiliate and any such employee.

 

(ii) Customers. The Executive
shall not, while he is employed by the Company and during the Restricted Period, solicit, contact, call upon, communicate with,
or attempt to solicit, contact, call upon, communicate with any Protected Customer (as hereinafter defined) to directly discourage
such Protected Customer from doing business with the Company or any of its subsidiaries or affiliates. For purposes of this Section
7, “Protected Customer” means any individual or entity to whom the Company or any subsidiary or affiliate thereof
has sold products or services or solicited to sell products or services during the final twelve (12) months of Executive’s
employment by the Company.

 

    	9

    	 

    

 

(b) Company IP; Work Product.

 

(i)“Intellectual
Property” means all intellectual property and industrial property recognized by applicable requirements of law and all
physical or tangible embodiments thereof, including all of the following, whether domestic or foreign: (1) patents and patent applications,
patent disclosures and inventions (whether or not patentable), as well as any reissues, continuations, continuations in part, divisions,
revisions, renewals, extensions or reexaminations thereof; (2) registered and unregistered trademarks, service marks, trade names,
trade dress, logos, slogans and corporate names, and other indicia of origin, pending trademark and service mark registration applications,
and intent-to-use registrations or similar reservations of marks; (3) registered and unregistered copyrights and mask works, and
applications for registration of either; (4) Internet domain names, applications and reservations therefor, uniform resource locators
and the corresponding Internet websites (including any content and other materials accessible and/or displayed thereon); (5) Confidential
Information; and (6) intellectual property and proprietary information not otherwise listed in (1) through (6) above, including
unpatented inventions, invention disclosures, rights of publicity, rights of privacy, moral and economic rights of authors and
inventors (however denominated), methods, artistic works, works of authorship, industrial and other designs, methods, processes,
technology, patterns, techniques, data, plant variety rights and all derivatives, improvements and refinements thereof, howsoever
recorded, or unrecorded; and (7) any goodwill associated with any of the foregoing, damages and payments for past or future infringements
and misappropriations thereof, and all rights to sue for past, present and future infringements or misappropriations thereof.

 

(ii)Work
Product. The Executive agrees to promptly disclose to the Company any and all work product, including Intellectual Property
relating to the business of the Company and any of its affiliates, that is created, developed, acquired, authored, modified, composed,
invented, discovered, performed, reduced to practice, perfected, or learned by the Executive (either solely or jointly with others)
directly relating to the Company’s and its affiliates’ business or within the scope of Executive’s employment
during the Term (collectively, “Work Product,” and together with such Intellectual Property as may be owned,
used, held for use, or acquired by the Company and its affiliates, the “Company IP”). The Company IP, including
the Work Product, is and shall be the sole and exclusive property of the Company and its affiliates, as applicable. All Work Product
that is copyrightable subject matter shall be considered a “work made for hire” to the extent permitted under applicable
copyright law (including within the meaning of Title 17 of the United States Code) and will be considered the sole property of
the Company. To the extent such Work Product is not considered a “work made for hire,” Executive hereby grants, transfers,
assigns, conveys and relinquishes, without any requirement of further consideration, all right, title, and interest to the Work
Product (whether now or hereafter existing, including all associated goodwill, damages and payments for past or future infringements
and misappropriations thereof and rights to sue for past and future infringements and misappropriates thereof) to the Company in
perpetuity or for the longest period permitted under applicable law. The Executive agrees, at the Company’s expense, to execute
any documents requested by the Company or any of its affiliates at any time to give full and proper effect to such assignment.
The Executive acknowledges and agrees that the Company is and will be the sole and absolute owner of all Intellectual Property,
including all Company IP. The Executive will cooperate with the Company and any of its affiliates, at no additional cost to such
parties (whether during or after the Term), in the confirmation, registration, protection and enforcement of the rights and property
of the Company and its affiliates in such intellectual property, materials and assets, including, without limitation, the Company
IP. The Executive hereby waives any so-called “moral rights of authors” in connection with the Work Product and acknowledges
and agrees that the Company may use, exploit, distribute, reproduce, advertise, promote, publicize, alter, modify or edit the Work
Product or combine the Work Product with other works including other Company IP, at the Company’s sole discretion, in any
format or medium hereafter devised. The Executive further waives any and all rights to seek or obtain any injunctive or equitable
relief in connection with the Work Product. Notwithstanding the above, the Executive shall have the right, subject to Section
6 hereof, to author or collaborate on one or more books or other similar works (in whatever form, including written, electronic
or otherwise) on any topic(s) whatsoever (including discussion of his experiences as an employee of the Company) (each, a “Book”),
and any such Book shall not be deemed Work Product or Company IP, and the Company shall have no claim to any rights, title or interest
in any such Book.

 

    	10

    	 

    

  

(c)Company Property. All Confidential
Information, Company IP, files, records, correspondence, memoranda, notes or other documents (including, without limitation, those
in computer-readable form) or property relating or belonging to the Company and its subsidiaries and affiliates, whether prepared
by the Executive or otherwise coming into his possession or control in the course of the performance of his services under this
Agreement, shall be the exclusive property of the Company and shall be delivered to the Company, and not retained by the Executive
(including, without limitation, any copies thereof), promptly upon request by the Company and, in any event, promptly upon termination
of Executive’s employment hereunder. Upon termination of Executive’s employment hereunder, the Executive shall have
no rights to and shall make no further use of any Company IP, including Work Product. The Executive acknowledges and agrees that
he has no expectation of privacy with respect to the Company’s telecommunications, networking or information processing systems
(including, without limitation, stored computer files, email messages and voice messages), and that the Executive’s activity
and any files or messages on or using any of those systems may be monitored at any time without notice. Nothing in this Section
7 shall require the Executive to return to the Company any computers or telecommunication equipment or tangible property which
he owns, including, but not limited to, personal computers, phones and tablet devices; provided, however, that Executive
shall identify each such device or item to the Company prior to termination of employment and afford the Company a reasonable opportunity
to remove from all such devices or items any confidential or proprietary information of the Company stored or programmed thereon.

 

(d)Enforcement.
The Executive acknowledges that a breach of his covenants and agreements contained in Sections 6 and 7 would cause irreparable
damage to the Company and its subsidiaries and affiliates, the exact amount of which would be difficult to ascertain, and that
the remedies at law for any such breach or threatened breach would be inadequate. Accordingly, the Executive agrees that if he
breaches or threatens to breach any of the covenants or agreements contained in Sections 6 and 7, in addition to any other
remedy which may be available at law or in equity, the Company and its subsidiaries and affiliates shall be entitled to institute
and prosecute proceedings in any court of competent jurisdiction for specific performance and injunctive and other equitable relief
to prevent the breach or any threatened breach thereof without bond or other security or a showing of irreparable harm or lack
of an adequate remedy at law. Additionally, upon a material breach by Executive of Section 6 or Section 7, the unvested
Restricted Stock (and any other stock-based awards held by the Executive) shall be automatically canceled and forfeited without
any further action. The Company and the Executive further acknowledge that the time, scope, geographic area and other provisions
of Sections 6 and 7 have been specifically negotiated by sophisticated commercial parties and agree that they consider the
restrictions and covenants contained in Sections 6 and 7 to be reasonable and necessary for the protection of the interests
of the Company and its subsidiaries and affiliates, but if any such restriction or covenant shall be held by any court of competent
jurisdiction to be void but would be valid if deleted in part or reduced in application, such restriction or covenant shall apply
in such jurisdiction with such deletion or modification as may be necessary to make it valid and enforceable. The Executive acknowledges
and agrees that the restrictions and covenants contained in Sections 6 and 7 shall be construed for all purposes to be separate
and independent from any other covenant, whether in this Agreement or otherwise, and shall each be capable of being reduced in
application or severed without prejudice to the other restrictions and covenants or to the remaining provisions of this Agreement.
The existence of any claim or cause of action by the Executive against the Company or any of its subsidiaries and affiliates, whether
predicated upon this Agreement or otherwise, shall not excuse the Executive’s breach of any covenant, agreement or obligation
contained in Section 6 or Section 7 and shall not constitute a defense to the enforcement by the Company or any of
its subsidiaries of such covenant, agreement or obligation; provided, however, that if upon termination of this Agreement
by the Company without “Cause” or by Executive for “Good Reason”, the Company defaults on any obligation
to pay Executive any amount due and owing Executive under Section 5(j)(ii)(1), then, until such time that the Company has
paid such amounts to Executive, Executive shall not be required to comply with the undertakings set forth in Section 7(a).

 

    	11

    	 

    

 

8.Indemnification. The Company
shall indemnify the Executive for actions taken by the Executive as an officer or director of the Company pursuant to the fullest
extent permitted by law; provided, however, that the Company shall not indemnify the Executive for any losses incurred
by the Executive as a result of or in connection with (a) acts or omissions described in Section 5(f), or (b) a cause of action
by Executive against the Company or its affiliates or their respective directors, officers, agents, representatives or employees.
If the Executive has any knowledge of any actual or threatened action, suit or proceeding, whether civil, criminal, administrative
or investigative, as to which the Executive may request indemnity under this provision, the Executive shall give the Company prompt
written notice thereof. The Company shall be entitled to assume the defense of any such proceeding, and the Executive shall cooperate
with such defense.

 

9.Section 409A of the Code.

 

(a)It is intended that the provisions
of this Agreement comply with Section 409A of Code and the regulations and guidance promulgated thereunder (collectively “Code
Section 409A”), and all provisions of this Agreement shall be construed in a manner consistent with the requirements
for avoiding taxes or penalties under Code Section 409A. If any provision of this Agreement (or of any award of compensation, including
equity compensation or benefits) would cause the Executive to incur any additional tax or interest under Code Section 409A, the
Company shall, upon the specific request of the Executive, use its reasonable business efforts to in good faith reform such provision
to comply with Code Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit
to the Executive and the Company of the applicable provision shall be maintained, but the Company shall have no obligation to make
any changes that could create any additional economic cost or loss of benefit to the Company. Notwithstanding the foregoing, the
Company shall have no liability with regard to any failure to comply with Code Section 409A so long as it has acted in good faith
with regard to compliance therewith.

 

    	12

    	 

    

 

(b)A termination of employment shall
not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits
upon or following a termination of employment unless such termination is also a “Separation from Service” within the
meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a “resignation,” “termination,”
“termination of employment” or like terms shall mean Separation from Service. Any provision of this Agreement to the
contrary notwithstanding, if at the time of the Executive’s Separation from Service, the Company determines that the Executive
is a “Specified Employee,” within the meaning of Code Section 409A, based on an identification date of December 31,
then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of such separation
from service would be considered nonqualified deferred compensation under Code Section 409A, such payment or benefit shall be paid
or provided at the date which is the earlier of (i) six (6) months and one day after such separation from service, and (ii) the
date of the Executive’s death (the “Delay Period”). Within five days of the end of the Delay Period, all
payments and benefits delayed pursuant to this Section 10(b) (whether they would have otherwise been payable in a single sum or
in installments in the absence of such delay) shall be paid or provided to the Executive in a lump-sum, and any remaining payments
and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them
herein.

 

(c)With regard to any provision herein
that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right
to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses
eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement,
or in-kind benefits to be provided, in any other taxable year, provided that the foregoing clause (ii) shall not be violated
with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses
are subject to a limit related to the period the arrangement is in effect and (iii) such payments shall be made on or before the
last day of the Executive’s taxable year following the taxable year in which the expense was incurred.

 

(d)Each payment made under this Agreement
shall be designated as a “separate payment” within the meaning of Code Section 409A.

 

    	13

    	 

    

 

10.Miscellaneous.

 

(a)This Agreement shall be deemed to
be a contract made under the laws of the State of New York and for all purposes shall be construed in accordance with those laws.
The Company and Executive unconditionally consent to submit to the exclusive jurisdiction of the New York State Supreme Court,
County of New York or the United States District Court for the Southern District of New York for any actions, suits or proceedings
arising out of or relating to this Agreement and the transactions contemplated hereby (and agree not to commence any action, suit
or proceeding relating thereto except in such courts), and further agree that service of any process, summons, notice or document
by registered mail to the address set forth below shall be effective service of process for any action, suit or proceeding brought
against the Company or the Executive, as the case may be, in any such court.

 

(b)Executive may not delegate his duties
or assign his rights hereunder. No rights or obligations of the Company under this Agreement may be assigned or transferred by
the Company other than pursuant to a merger or consolidation in which the Company is not the continuing entity, or a sale, liquidation
or other disposition of all or substantially all of the assets of the Company, provided that the assignee or transferee
is the successor to all or substantially all of the assets or businesses of the Company and assumes the liabilities, obligations
and duties of the Company under this Agreement, either contractually or by operation of law. For the purposes of this Agreement,
the term “Company” shall include the Company and, subject to the foregoing, any of its successors and assigns. This
Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their respective heirs, legal representatives,
successors and permitted assigns.

 

(c)The invalidity or unenforceability
of any provision hereof shall not in any way affect the validity or enforceability of any other provision. This Agreement reflects
the entire understanding between the parties.

 

(d)This Agreement represents the entire understanding
of the Executive and the Company with respect to the employment of the Executive by the Company and contain all of the covenants
and agreements between the parties with respect to such employment. Any modification or termination of this Agreement will be effective
only if it is in writing signed by the party to be charged.

 

(e)This Agreement may be executed by
the parties in one or more counterparts, each of which shall be deemed to be an original but all of which taken together shall
constitute one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the
parties hereto and delivered to each of the other parties hereto.

 

(f)All amounts payable hereunder shall
be subject to the withholding of all applicable taxes and deductions required by any applicable law.

 

11.Notices. All notices relating
to this Agreement shall be in writing and shall be either personally delivered, sent by telecopy (receipt confirmed) or mailed
by certified mail, return receipt requested, to be delivered at such address as is indicated below, or at such other address or
to the attention of such other person as the recipient has specified by prior written notice to the sending party. Notice shall
be effective when so personally delivered, one business day after being sent by telecopy or five days after being mailed.

 

    	14

    	 

    

 

To the Company:

 

Sequential Brands Group, Inc.

1065 Avenue of Americas

New York, NY 10018

Attention: Yehuda Shmidman

 

With a copy to:

 

Sequential Brands Group, Inc.

c/o Tengram Capital Management, LLC

15 Riverside Avenue

Westport, CT 06880

Attention: Andrew R. Tarshis

  

To the Executive:

 

[signature pages follows]

 

    	15

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have
executed this agreement as of the 3rd day of June, 2014.

 

SEQUENTIAL BRANDS GROUP, INC.

 

	By: 	/s/ William Sweedler
	 	William Sweedler
	 	Chairman

 

EXECUTIVE

 

	By:  	/s/ Gary Klein
	 	Gary Klein
	 	CFO

 

    	16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]